AxoGen Inc. (AXGN) Rating Reiterated by Wedbush
AxoGen Inc. (NASDAQ:AXGN)‘s stock had its “outperform” rating restated by equities researchers at Wedbush in a research note issued on Friday. They currently have a $12.00 price objective on the stock. Wedbush’s price objective would suggest a potential upside of 36.36% from the stock’s current price.
A number of other equities research analysts also recently weighed in on AXGN. JMP Securities reaffirmed a “buy” rating on shares of AxoGen in a research report on Tuesday, November 22nd. Lake Street Capital downgraded shares of AxoGen from a “buy” rating to a “hold” rating and set a $9.00 price objective for the company. in a research report on Thursday, November 3rd.
Shares of AxoGen (NASDAQ:AXGN) opened at 8.45 on Friday. The firm’s market capitalization is $277.99 million. The stock’s 50 day moving average is $8.66 and its 200-day moving average is $7.71. AxoGen has a 52-week low of $4.52 and a 52-week high of $9.88.
AxoGen (NASDAQ:AXGN) last announced its quarterly earnings data on Wednesday, November 2nd. The company reported ($0.08) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.08). AxoGen had a negative net margin of 33.02% and a negative return on equity of 292.94%. On average, equities analysts forecast that AxoGen will post ($0.38) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US & international copyright and trademark laws. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2016/11/29/axogen-inc-axgn-rating-reiterated-by-wedbush.html.
In other news, CEO Karen L. Zaderej bought 10,000 shares of the firm’s stock in a transaction on Friday, October 7th. The stock was purchased at an average price of $7.50 per share, for a total transaction of $75,000.00. Following the transaction, the chief executive officer now owns 242,147 shares in the company, valued at $1,816,102.50. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Amy Mcbride Wendell bought 13,333 shares of the firm’s stock in a transaction on Friday, October 7th. The stock was purchased at an average price of $7.50 per share, with a total value of $99,997.50. Following the transaction, the director now owns 13,333 shares in the company, valued at approximately $99,997.50. The disclosure for this purchase can be found here. 9.33% of the stock is currently owned by company insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of AXGN. Vanguard Group Inc. boosted its position in AxoGen by 61.5% in the second quarter. Vanguard Group Inc. now owns 775,448 shares of the company’s stock valued at $5,335,000 after buying an additional 295,294 shares during the period. BlackRock Fund Advisors boosted its position in AxoGen by 7.3% in the third quarter. BlackRock Fund Advisors now owns 680,329 shares of the company’s stock valued at $6,143,000 after buying an additional 46,197 shares during the period. BlackRock Institutional Trust Company N.A. boosted its position in AxoGen by 15.8% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 303,249 shares of the company’s stock valued at $2,738,000 after buying an additional 41,414 shares during the period. State Street Corp purchased a new position in AxoGen during the second quarter valued at approximately $1,885,000. Finally, Summit Partners Public Asset Management LLC purchased a new position in AxoGen during the third quarter valued at approximately $2,376,000. Hedge funds and other institutional investors own 52.42% of the company’s stock.
Receive News & Stock Ratings for AxoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen Inc. and related stocks with our FREE daily email newsletter.